Label Expansion and Global Progress
FDA Expanded Approval: On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved our supplemental Biologics License Application (sBLA) expanding the approved
Partnership brings first-in-class IL-15 receptor agonist immunotherapy to patients in Israel
Israeli Ministry of Health grants approval for ANKTIVA® (nogapendekin alfa inbakicept) in combination with BCG for adult
ANKTIVA® plus BCG met the primary efficacy endpoint in the randomized registrational trial of 370 subjects comparing intravesical ANKTIVA plus BCG with BCG alone; additional study details will be presented at an
First patients treated in Germany and Austria, with commercial support from Accord Healthcare
Treatment milestone follows European Commission’s February 2026 conditional marketing authorization of ANKTIVA in
Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle invasive bladder
Peer-reviewed publication reports long-term outcomes from the QUILT-3.032 study supporting durable disease control and bladder preservation
ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today
Expanded indication extends ANKTIVA plus BCG to patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), including those with carcinoma in situ (CIS), with or without papillary tumors, and those with
ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Global Chief Scientific and Medical Officer, will participate
DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com)— Today’s market is driven by an outstanding mix of listings, including Alpha Modus Holdings (NASDAQ:AMOD), Stablecoin Development (NYSEAMERICAN:SDEV),
TORONTO, Oct. 1, 2026 /CNW/ -- HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors
Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB)
Dr. Kim will advise on international partnerships and global access initiatives through the newly formed Office of the Executive Chairman
ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today
Q2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially from Q1 2026, marking the eighth consecutive quarter of sequential revenue growth since the commercial launch of ANKTIVA®,
The UAE authorization further expands ANKTIVA’s global regulatory footprint to 34 countries. The BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) authorization is the first worldwide to span the full
Issued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while
